[{"data":1,"prerenderedAt":133},["ShallowReactive",2],{"drug-glycopyrronium-cloth":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":55,"warnings":65,"renal":66,"monitoring":67,"interactions":68,"review":69,"examples":72,"atc":73,"iran":75,"usApproval":82,"links":88,"populations":99},"glycopyrronium-cloth",1,{"fa":7,"en":8},"دستمال گلیکوپیرونیوم (تعریق زیر بغل)","Glycopyrronium cloth","dermatology",{"fa":11,"en":12},"آنتی‌کولینرژیک موضعی","Topical anticholinergic",[14],{"name":15,"market":16},"Qbrexza","US",[18,19],"qbrexza","گلیکوپیرونیوم",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"cloth","cream","topical","Single-use cloth with 2.4% glycopyrronium",{"amount":5,"unit":27,"perUnit":27},"application",[16],[30],{"source":31,"section":32},"fda-qbrexza","3",[34],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":45,"dose":46,"refs":50},"axilla","hyperhidrosis",{"fa":38,"en":39},"تعریق اولیه زیر بغل (۹ سال به بالا) — یک دستمال روزانه برای هر دو زیر بغل","Primary axillary hyperhidrosis (≥9 y) — one cloth daily for both underarms",{"minAge":41},{"value":42,"unit":43},9,"year","notCalculated","mg",{"reason":47},{"fa":48,"en":49},"روی پوست تمیز و خشک فقط زیر بغل؛ یک دستمال یک بار روی هر زیر بغل؛ حداکثر هر ۲۴ ساعت یک بار. پس از مصرف دست‌ها شسته شود (تاری دید با تماس چشم).","On clean dry underarm skin only; wipe one cloth once across each underarm; no more than once every 24 h. Wash hands afterwards (blurred vision if it reaches the eyes).",[51,53],{"source":31,"section":52},"2",{"source":31,"section":54},"1",[56],{"id":57,"severity":58,"text":59,"refs":62},"ci","block",{"fa":60,"en":61},"بیماری‌هایی که با اثر آنتی‌کولینرژیک بدتر می‌شوند: گلوکوم، ایلئوس فلجی، وضعیت ناپایدار قلبی در خونریزی، کولیت اولسروز شدید، مگاکولون توکسیک، میاستنی گراویس، شوگرن.","Conditions worsened by anticholinergic effects: glaucoma, paralytic ileus, unstable cardiovascular status in haemorrhage, severe ulcerative colitis, toxic megacolon, myasthenia gravis, Sjögren’s.",[63],{"source":31,"section":64},"4",[],[],[],[],{"status":70,"reviewer":71,"date":71},"unverified",null,[],[74],"D11AA01",{"status":76,"refs":77},"not-found",[78],{"source":79,"section":80,"url":81},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Glycopyrronium%20cloth",{"kind":83,"refs":84,"id":87},"NDA",[85],{"source":31,"section":86},"SPL approval \u002F marketing category","NDA210361",[89,92,96],{"kind":90,"url":91,"label":87},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=210361",{"kind":93,"url":94,"label":95},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5b372650-e56e-47a5-93e2-c0c292017059","FDA Qbrexza",{"kind":97,"url":98,"label":74},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=D11AA01",{"pregnancy":100,"lactation":109,"pediatric":117,"geriatric":125},{"level":101,"text":102,"quote":105,"refs":106},"caution",{"fa":103,"en":104},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on Qbrexza use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.",[107],{"source":31,"section":108},"8.1",{"level":101,"text":110,"quote":113,"refs":114},{"fa":111,"en":112},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.",[115],{"source":31,"section":116},"8.2",{"level":101,"text":118,"quote":121,"refs":122},{"fa":119,"en":120},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety, effectiveness and pharmacokinetics of Qbrexza have been established in pediatric patients age 9 years and older for topical treatment of primary axillary hyperhidrosis [see Clinical Pharmacology ( 12.3 )] .",[123],{"source":31,"section":124},"8.4",{"level":101,"text":126,"quote":129,"refs":130},{"fa":127,"en":128},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical trials of Qbrexza did not include sufficient numbers of subjects age 65 years and older to determine whether they respond differently from younger subjects.",[131],{"source":31,"section":132},"8.5",1792115182136]